Chitosan-containing medicinal preparation, medicinal transdermal patch and preparation method of medicinal transdermal patch

A technology of pharmaceutical preparations and transdermal patches, applied in the field of medicine

Active Publication Date: 2020-12-22
江苏一全药业有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing transdermal patches are still difficult to achieve long-lasting (up to 5-7 days) effective release, and new absorption enhancers may bring new risks to the human body

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chitosan-containing medicinal preparation, medicinal transdermal patch and preparation method of medicinal transdermal patch
  • Chitosan-containing medicinal preparation, medicinal transdermal patch and preparation method of medicinal transdermal patch
  • Chitosan-containing medicinal preparation, medicinal transdermal patch and preparation method of medicinal transdermal patch

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A1

[0096] (1) Prepare packaged medicine

[0097] 0.28g olanzapine is dissolved in chitosan (molecular weight is 180,000) shown in 0.41g formula (1) and chitosan derivative shown in 0.21g formula (2) (molecular weight is 150,000, acylation degree is 1) in the aqueous solution to obtain the water phase; add the obtained water phase to 15 times the weight of the oil phase (which contains 0.2g emulsifier Tween-80, the rest is petroleum ether, the following are the same), ultrasonic 30min, forming W / The O-type emulsion is added with a cross-linking agent glutaraldehyde to carry out chemical cross-linking, and the obtained material is centrifuged and dried to obtain olanzapine-chitosan coatings with an average particle diameter of 387nm.

[0098] (2) Ingredients

[0099] Encapsulated drug: prepared in this embodiment;

[0100] Unpacked drug: olanzapine, 0.1g;

[0101] Transdermal absorption enhancer: isopropyl myristate, 0.57g;

[0102] Drug-loaded matrix: 7.17g in total, of which...

Embodiment A2

[0108] (1) Prepare packaged medicine

[0109] 0.25g olanzapine is dissolved in chitosan (molecular weight is 150,000) shown in 0.46g formula (1) and chitosan derivative shown in 0.19g formula (3) (molecular weight is 200,000, acylation degree is 1) into an aqueous solution to obtain a water phase; add the obtained water phase to 12 times the weight of the oil phase, and ultrasonicate for 30 minutes to form a W / O emulsion, then add a cross-linking agent glutaraldehyde for chemical cross-linking, and centrifuge the obtained material Separating and drying to obtain the olanzapine chitosan coating with an average particle diameter of 354nm.

[0110] (2) Ingredients

[0111] Encapsulated drug: prepared in this embodiment;

[0112] Unpacked drug: olanzapine, 0.1g;

[0113] Transdermal absorption enhancer: isopropyl myristate, 0.42g;

[0114] Drug-loading matrix: a total of 7.5g, of which 6.00g is 235A pressure-sensitive adhesive (containing carboxyl group), 0.75g is 2516 pressur...

Embodiment A3

[0120] 0.22g olanzapine is dissolved in chitosan (molecular weight is 200,000) shown in 0.41g formula (1) and chitosan derivative shown in 0.25g formula (4) (molecular weight is 180,000, acylation degree is 2) into an aqueous solution to obtain a water phase; add the obtained water phase to 10 times the weight of the oil phase, and ultrasonicate for 30 minutes to form a W / O emulsion, then add a cross-linking agent glutaraldehyde for chemical cross-linking, and centrifuge the obtained material Separating and drying to obtain the olanzapine chitosan coating with an average particle diameter of 436nm.

[0121] (2) Ingredients

[0122] Encapsulated drug: prepared in this embodiment;

[0123] Unpacked drug: olanzapine, 0.1g;

[0124] Transdermal absorption enhancer: Span 20, 0.7g;

[0125] Drug-loaded matrix: a total of 7.64g, of which 4.59g is 2852 pressure-sensitive adhesive (containing carboxyl group), and 3.06g is 2516 pressure-sensitive adhesive (containing hydroxyl group);...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of medicines, in particular to a medicinal preparation, a medicinal transdermal patch containing the medicinal preparation and a preparation method of the medicinaltransdermal patch. The pharmaceutical preparation comprises a coated drug and an uncoated drug, wherein the coated drug comprises a drug A and an inclusion material coating the drug A, and the inclusion material contains chitosan and / or derivatives thereof; the uncoated drug is a drug B; and the drug A and the drug B are the same or different. The medicinal preparation and the medicinal transdermal patch can release an effective dose of drugs lastingly (7 days) and stably, and have stronger controllability so as to meet the medication requirements of patients with different degrees.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical preparation, a drug transdermal patch containing the pharmaceutical preparation and a preparation method thereof. Background technique [0002] External treatment is a commonly used method in clinical practice. In the early days, it was mostly in the form of Chinese herbal plasters, which were used to apply acupoints or local injuries to achieve therapeutic effects. This treatment method is simple and easy to operate, and has a high degree of patient acceptance. [0003] In addition, for Western medicines that are traditionally taken orally or injected, transdermal patches have appeared in recent years to replace oral or injected. On the other hand, it can increase patient acceptance. However, it is still difficult for the drug to release an effective dose through the stratum corneum of the skin, and the penetration dose, stability and duration have not been ideal. In t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/70A61K47/69A61K31/551A61P25/18
CPCA61K9/7061A61K31/551A61K47/6949A61K47/6951A61P25/18
Inventor 全丹毅
Owner 江苏一全药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap